Health & Environmental Research Online (HERO)


Print Feedback Export to File
8617696 
Journal Article 
Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost 
Mohammed El Tabaa, M; Mohammed El Tabaa, M 
2020 
Yes 
Biochemical Pharmacology
ISSN: 0006-2952
EISSN: 1873-2968 
178 
114057 
English 
COVID-19 is an ongoing viral pandemic disease that is caused by SARS-CoV2, inducing severe pneumonia in humans. However, several classes of repurposed drugs have been recommended, no specific vaccines or effective therapeutic interventions for COVID-19 are developed till now. Viral dependence on ACE-2, as entry receptors, drove the researchers into RAS impact on COVID-19 pathogenesis. Several evidences have pointed at Neprilysin (NEP) as one of pulmonary RAS components. Considering the protective effect of NEP against pulmonary inflammatory reactions and fibrosis, it is suggested to direct the future efforts towards its potential role in COVID-19 pathophysiology. Thus, the review aimed to shed light on the potential beneficial effects of NEP pathways as a novel target for COVID-19 therapy by summarizing its possible molecular mechanisms. Additional experimental and clinical studies explaining more the relationships between NEP and COVID-19 will greatly benefit in designing the future treatment approaches. 
Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Peptide Fragments; Angiotensin I; 9041-90-1; Neprilysin; EC 3.4.24.11; angiotensin I (1-7); IJ3FUK8MOF; Index Medicus; Bradykinins; Ang (1–7); Coronavirus disease; Endothelin-1; COVID-19; SARS-CoV-2; Angiotensin Receptor Antagonists -- therapeutic use; Angiotensin I -- pharmacology; Angiotensin I -- therapeutic use; Peptide Fragments -- pharmacology; Angiotensin-Converting Enzyme Inhibitors -- therapeutic use; Angiotensin-Converting Enzyme Inhibitors -- pharmacology; Angiotensin Receptor Antagonists -- pharmacology; Peptide Fragments -- therapeutic use; Drug Repositioning -- trends; Pneumonia, Viral -- virology; Neprilysin -- metabolism; Pandemics -- prevention & control; Betacoronavirus -- physiology; Betacoronavirus -- drug effects; Antiviral Agents -- therapeutic use; Pneumonia, Viral -- prevention & control; Signal Transduction -- drug effects; Coronavirus Infections -- prevention & control; Neprilysin -- antagonists & inhibitors; Drug Repositioning -- methods; Antiviral Agents -- pharmacology; Coronavirus Infections -- physiopathology; Coronavirus Infections -- virology; Drug Repositioning -- statistics & numerical data; Pneumonia, Viral -- physiopathology